Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Terminated
- Estimated Enrollment
- 30
Summary
- Conditions
- Malignant Melanoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Secondarily to studying the efficacy of the treatment; the investigators examine if treatment with IDO/Survivin peptide can induce a measurable cellular T-cell response when the vaccine is given in combination with temozolomide treatment for melanoma patients.
Secondarily to studying the efficacy of the treatment; the investigators examine if treatment with IDO/Survivin peptide can induce a measurable cellular T-cell response when the vaccine is given in combination with temozolomide treatment for melanoma patients.
Tracking Information
- NCT #
- NCT01543464
- Collaborators
- Copenhagen University Hospital at Herlev
- Investigators
- Principal Investigator: Trine Zeeberg Iversen, MD Center for Cancer ImmuneTherapy Study Director: Inge Marie Svane, MD, PhD, Prof. Center for Cancer ImmunoTherapy
Get Well Soon